What’s different in your drug stores this month? A battery-powered toothbrush for sensitive teeth and gums. A pivoting shower and bath safety grip bar. The smallest size (to date) fish oil softgels. Insoles for multiple shoe styles to help take care of various foot comfort problems. A yeast-based probiotic supplement. A “fishless†omega-3 product for vegetarians. And there are even more new over-the-counter items featured in the print edition of Drug Topics.
The Office of Inspector General has issued a report implicating more than 2,600 pharmacies in Medicare Part D fraud
FDA says no to rivaroxaban for ACS. ACCP updates DVT evidence. Fatal bleeds from dabigatran have tapered off
The business of pharmacy is crushing the profession. The bean counters are running the Prescription Mill right into the ground. And if we don't stop them, who will be left to do our jobs?
Pharmacy associations offered a range of comments after the Supreme Court ruling that upheld key elements of the Affordable Care Act
We've already felt the pain. When will we go for the gain? How many physical breakdowns, ruined home lives, and professional traumas is it gonna take before we finally say enough is enough and ORGANIZE?
In a competitive profession and an age of limits, the formula for success is still pretty simple: Sell yourself - and then deliver!
A round-up of OTC products to treat eye and ear problems
CMS is assessing genetic testing for the older population
Recent changes to Medicaid's reimbursement rules raise many confusing questions. Drug Topics' senior legal columnist sets out to clarify some key points
Adding pharmacists to the hospital discharge process is shown to have a positive effect on combating hospital readmission rates
Maybe the best way to change the environment in pharmacy is to have an old-fashioned '60s-style protest
FDA approves avanafil and tafluprost
Drug Topics and the Office of Pharmacy Development, University of Connecticut School of Pharmacy, introduce a new three-phase practice-based activity: "Medication Therapy Management for Patients with Diabetes"
A survey of new Rx, new generic, and new OTC products
Bacterial contaminants have been traced back to a robot in a Winston-Salem, N.C. health center pharmacy
It was a regulatory milestone, yet the expected leap forward for personalized medicine never happened. But all may not yet be lost
Readers share their rules for getting through the day, memories of technologies past, and a call to arms
FDA is alerting healthcare professionals to the possibility that a 32-mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) could lead to QT interval prolongation, putting patients at risk for a potentially fatal heart rhythm known as Torsades de Pointes.
FDA has approved the marketing of the first nucleic acid test that can identify in less than 3 hours 12 different bacterial types known to cause bloodstream infections.
Comorbidity from chronic diseases and severity of illness increased the likelihood of adverse drug reactions in senior patients, according to a new study published online June 26 in the Annals of Pharmacotherapy.
Annual global spending on medicines will reach nearly $1.2 trillion by 2016, while U.S. spending growth is projected to soar to between $350 and $380 billion by 2016, according to a new report.
FDA recently released the results of an analysis of a limited number of samples of hydroxyprogesterone caproate active pharmaceutical ingredients and compounded hydroxyprogesterone caproate, finding no major safety concerns.
Lupin has received FDA approval to market a generic version of Lyrica (Pfizer), but the company has not yet launched it, according to Firstword Pharma.
Patients treated with olmesartan may be at risk of a severe form of spruelike enteropathy, which improves when the drug is discontinued, according to a case series study published online June 25 in Mayo Clinic Proceedings.
